erlotinib hydrochloride has been researched along with Diabetes Mellitus, Type 2 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duell, T; Gaertner, S; Genzel, R; Knyazev, PG; Morresi-Hauf, A; Ullrich, A; Xiao, Z | 1 |
| Chung, S; Fan, X; Harris, RC; Li, Y; Li, Z; Niu, A; Overstreet, JM; Wang, S; Wang, Y; Zhang, MZ | 1 |
| Alejandre, MJ; Aránega, A; Caba, O; Delgado, JR; Iglesias, J; Irigoyen, A; Linares, A; Martin, M; Ortuño, FM; Palomino, RJ; Perales, S; Prados, JC; Rojas, I; Torres, C | 1 |
| Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W | 1 |
| Costa, DB; Huberman, MS | 1 |
5 other study(ies) available for erlotinib hydrochloride and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Diabetes Mellitus, Type 2; ErbB Receptors; Erlotinib Hydrochloride; Humans; Metformin; Mice; Neoplasm Proteins; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2017 |
Inhibition of Epidermal Growth Factor Receptor Activation Is Associated With Improved Diabetic Nephropathy and Insulin Resistance in Type 2 Diabetes.
Topics: Albuminuria; Animals; Biomarkers; Crosses, Genetic; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; ErbB Receptors; Erlotinib Hydrochloride; Fibrosis; Glomerulonephritis; Hypoglycemic Agents; Insulin Resistance; Kidney; Macrophages; Membrane Transport Modulators; Mice, Knockout; Mice, Mutant Strains; Nitric Oxide Synthase Type III; Oxidative Stress; Protein Kinase Inhibitors; T-Lymphocytes; Transforming Growth Factor alpha | 2018 |
Serum cytokine profile in patients with pancreatic cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Comorbidity; Cytokines; Deoxycytidine; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking; Tumor Microenvironment | 2014 |
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Glyburide; Humans; Lung Neoplasms; Pioglitazone; Quinazolines; Thiazolidinediones | 2006 |